[Skip to Content]
[Skip to Content Landing]
Commentary
May 27, 1998

Lipid-Lowering Therapy in Low-Risk Patients

Author Affiliations

From the University of Rochester School of Medicine, Rochester, NY.

JAMA. 1998;279(20):1659-1661. doi:10.1001/jama.279.20.1659

In this issue of THE JOURNAL, Downs et al1 present the primary results of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). The study is yet another randomized, placebo-controlled, clinical trial of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, in this case lovastatin, as a means to prevent atherosclerotic coronary artery disease. Although readers might wonder what such a trial might add to understanding the role of lipid-lowering therapy in general, or of the use of the so-called statins in particular, this trial is of singular importance and timeliness to guide the use of these agents in the controversial area of the primary prevention of cardiovascular disease.

×